Sign In
Buy ABEO
$5.67
-0.0200 (-0.351%)
At Close: Jun 03, 2026
Abeona Therapeutics (NASDAQ:ABEO) Releases Quarterly Earnings Results, Hits Expectations
05:12pm, Tuesday, 16'th Nov 2021 Dakota Financial News
Abeona Therapeutics (NASDAQ:ABEO) posted its quarterly earnings data on Sunday. The biopharmaceutical company reported ($0.16) EPS for the quarter, hitting the consensus estimate of ($0.16), Fidelity Earnings reports. Abeona Therapeutics stock traded down $0.02 during mid-day trading on Tuesday, hitting $0.89. The stock had a trading volume of 201 shares, compared to its average volume […]
Abeona Therapeutics (NASDAQ:ABEO) Posts Earnings Results, Hits Estimates
12:48pm, Tuesday, 16'th Nov 2021 Transcript Daily
Abeona Therapeutics (NASDAQ:ABEO) released its quarterly earnings results on Sunday. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, hitting the Zacks consensus estimate of ($0.16), Fidelity Earnings reports. Shares of NASDAQ:ABEO opened at $0.91 on Tuesday. The company has a market cap of $92.18 million, a P/E ratio of -1.57 and a []
Abeona Therapeutics Announces Participation at the Jefferies London Healthcare Conference
12:30pm, Tuesday, 16'th Nov 2021 GlobeNewswire Inc.
NEW YORK and CLEVELAND, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Vish Seshadri, Ph.D., Chie
Abeona Therapeutics Announces Participation at the Jefferies London Healthcare Conference
12:30pm, Tuesday, 16'th Nov 2021 Investors Abeona Therapeutics
Abeona Therapeutics Reports Third Quarter Financial Results
12:45pm, Monday, 15'th Nov 2021 Intrado Digital Media
Phase 3 VIITAL study on track to complete enrollment in first quarter 2022 with final patients identified and under screening
ABEO : ABEO posts H1 2021/22 revenue up 14.1% and solid order intake up 25.7%
06:30am, Monday, 15'th Nov 2021 Actusnews
Full and original release on www.actusnews.com . Subscribe to this company''s information.
Abeona Therapeutics to Present at Jefferies Gene Therapy/Editing Summit
07:30am, Thursday, 21'st Oct 2021
NEW YORK and CLEVELAND, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Vish Seshadri, Ph.D., M.B.A.
Abeona Therapeutics Announces Clinical Data Presentations at Upcoming Scientific Congresses
07:30am, Wednesday, 13'th Oct 2021
NEW YORK and CLEVELAND, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced two presentations of previously d
Abeona Therapeutics Appoints Gene Therapy Quality Leader Jon Voss as Vice President, Head of Quality
07:30am, Tuesday, 12'th Oct 2021
NEW YORK and CLEVELAND, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Jon Voss as Vi
Steven H. Rouhandeh to retire as Chairman of the Board; Michael Amoroso appointed Chairman of the Board
Abeona Therapeutics to Present at Upcoming Investor Conferences
07:30am, Tuesday, 07'th Sep 2021
NEW YORK and CLEVELAND, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that members of the company's ma
Abeona Therapeutics Appoints Edward Carr as Chief Financial Officer
07:30am, Tuesday, 10'th Aug 2021
NEW YORK and CLEVELAND, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Edward Carr as
Abeona Therapeutics Reports Second Quarter Financial Results
04:01pm, Wednesday, 28'th Jul 2021
Second clinical trial site activated in EB-101 pivotal Phase 3 VIITAL™ study
Abeona Stock Gains As It Concludes Type B Meeting With FDA For MPS IIIA Gene Therapy
10:53am, Wednesday, 28'th Jul 2021
Abeona Therapeutics Inc (NASDAQ: ABEO) has completed a Type B meeting with the FDA regarding the pivotal trial for its ABO-102 gene therapy for Sanfilippo syndrome type A (MPS IIIA). ABO-102 is c
